Therapeutic potential of thromboxane inhibitors in asthma

Expert Opinion on Investigational Drugs

Volumn 11, Issue 2, 2002, Pages 275-281

  Dogné, Jean Michel ^a   de Leval, Xavier ^a   Benoit, Patricia ^a   Rolin, Stephanie ^a   Pirotte, Bernard ^a   Masereel, Bernard ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Asthma; Thromboxane A2; Thromboxane inhibitors; Thromboxane modulators

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ANTIASTHMATIC AGENT; ARACHIDONIC ACID; AUTACOID; AZELASTINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL RESPONSE MODIFIER; LEUKOTRIENE; METHACHOLINE; OZAGREL; PLACEBO; PROSTAGLANDIN; RAMATROBAN; SERATRODAST; STEROID; THROMBOXANE A2; THROMBOXANE RECEPTOR BLOCKING AGENT; THROMBOXANE SYNTHASE INHIBITOR; THROMBOXANE RECEPTOR;

AIRWAY OBSTRUCTION; ALLERGIC ASTHMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARACHIDONIC ACID METABOLISM; ASTHMA; BRONCHITIS; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; CLINICAL FEATURE; CLINICAL STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; NONHUMAN; PATHOGENESIS; REVIEW; DRUG ANTAGONISM; METABOLISM;

ASTHMA; HUMANS; LEUKOTRIENES; PROSTAGLANDINS; RECEPTORS, THROMBOXANE; THROMBOXANE A2;

EID: 0036166269     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.2.275     Document Type: Review

References (82)

1. Arachidonic acid metabolites: Mediators of inflammation in asthma
2. 2 and related prostaglandins in airways
3. Leukotriene and thromboxane antagonists
4. 2 biosynthesis in acute asthma and after antigen challenge
5. 2 in the pathogenesis of airway hyperresponsiveness
6. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients
7. Measurement of peptidoleukotrienes in biological fluids
8. Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma
9. Discovery of leukotrienes and development of antileukotriene agents
10. Role of leukotrienes in asthma pathophysiology
11. Biochemistry and physiology of the leukotrienes
12. Leukotriene receptor antagonists in the treatment of asthma
13. Efficacy of antileukotriene agents in asthma management
14. Arachidonic acid metabolism by human monocytes. Studies with plateletdepleted cultures
15. 2- and allergen-induced bronchoconstriction
16. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides
17. 2
18. Difference in urinary LTE4 and 11-dehydro-TXB2 excretion in asthmatic patients
19. Can urinary eicosanoids be a potential predictive marker of clinical response to thromboxane A2 receptor antagonist in asthmatic patients?
20. 2: Effects on airway and vascular smooth muscle
21. Change in responsiveness of airway and beta-adrenoceptor in guinea pigs
22. Airway hyperresponsiveness induced by platelet-activating factor: Role of thromboxane generation
23. 4-mediated bronchoconstriction in the guinea pig
24. 4 in guinea-pigs
25. 4 induces airway hyperresponsiveness in dogs
26. 4 in guinea pigs
27. Endothelin-1 induces stimulation of prostaglandin synthesis in cells obtained from canine airways by bronchoalveolar lavage
28. Mechanisms of endotoxin-induced airway and pulmonary vascular hyperreactivity in mice
29. Significance of thromboxane generation in ozone-induced airway hyperresponsiveness in dogs
30. 2 synthetase inhibitors in the treatment of patients with bronchial asthma
31. The effect of GR32191 on airway responsiveness in asthma
32. Effects of a thromboxane synthetase inhibitor (OKY-046) and a lipoxygenase inhibitor (AA-861) on bronchial responsiveness to acetylcholine in asthmatic subjects
33. Effects of aerosol administration of a thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to acetylcholine in asthmatic subjects
34. 2 receptor antagonist (AA-2414) on bronchial hyperresponsiveness to methacholine in subjects with asthma
35. Effect of an inhaled thromboxane mimetic (U46619) on airway function in human subjects
36. Modulation of cholinergic neurotransmission in canine airways by thromboxane mimetic U46619
37. Potentiation of vagal contractile response by thromboxane mimetic U-46619
38. 2 receptor antagonist, on neuro-effector transmission in canine tracheal tissue
39. 2 synthase
40. 4-induced bronchoconstriction in guinea pigs
41. Effect of an oral thromboxane synthetase inhibitor (OKY-046) on antigen-induced bronchoconstriction in guinea pigs
42. 2 synthetase inhibitor, in guinea pigs
43. Pharmacological studies of platelet-activating factor (PAF)-induced augmentation of response to histamine in guinea-pigs
44. 2) in guinea pigs
45. Inhibition of antigen-induced airway hyperresponsiveness by a thromboxane synthetase inhibitor (OKY-046) in allergic dogs
46. 2 synthetase inhibitor (OKY-046.HCI) on airway hyperresponsiveness in guinea pigs
47. Airway hyperresponsiveness to acetylcholine induced by aerosolized arachidonic acid metabolites in guinea-pigs
48. Attenuating effect of a thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to methacholine is specific to bronchial asthma
49. Clinical efficacy of OKY-046 in bronchial asthma in a multicenter, double-blind study
50. Utility of OKY-046, a selective thromboxane synthetase inhibitor, on adult bronchial asthma in a multicenter, comparative, double-blind clinical study with azelastine hydrochloride
51. 2 synthetase inhibitor, ozagrel hydrochloride, for preeclampsia
52. Efficacy and toxicity of thromboxane synthetase inhibitor for cerebral vasospasm after subarachnoid hemorrhage
53. Clinical study of OKY-046, a thromboxane synthetase inhibitor, in prevention of cerebral vasospasms and delayed cerebral ischaemic symptoms after subarachnoid haemorrhage due to aneurysmal rupture: A randomized double-blind study
54. Clinical effects of sodium ozagrel and urokinase in patients with acute cerebral infarction in the territory of the internal carotid artery
55. A novel anti-asthmatic quinone derivative, AA-2414 with a potent antagonistic activity against a variety of spasmogenic prostanoids
56. Quinones. 4. Novel eicosanoid antagonists: Synthesis and pharmacological evaluation
57. 2 receptor antagonistic activity of phenol derivatives
58. 2 receptor by an anti-asthmatic agent AA-2414
59. 2 antagonist-discovery of seratrodast
60. Pharmacological modulation of immediate and late airway response and leukocyte infiltration in the guinea pig
61. 2 antagonist, AA-2414 on airway hyperresponsiveness induced by ozone exposure in dogs
62. 2 receptor antagonist (AA-2414) in Ascaris suum-allergic dogs
63. 2 receptor antagonist, on airway inflammation in subjects with asthma
64. 2 antagonist on sputum production and its physicochemical properties in patients with mild to moderate asthma
65. Correlation between the clinical effects of seratrodast and the level of 11-dehydro-TXB2 in urine/sputum in bronchial asthma patients
66. Action of the novel selective thromboxane antagonist (3R)-3-(4 -fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazolepropanoic acid on vascular smooth muscle preparations
67. Prostanoid contractions in human isolated pulmonary muscle preparations: Inhibition by BAY u3405
68. 2 alpha-induced contractions of airway smooth muscle
69. Inhibitory effects of BAY u3405 on prostanoid-induced contractions in human isolated bronchial and pulmonary arterial muscle preparations
70. 2-induced bronchoconstriction in the guinea-pig
71. 2 receptor antagonist on airway smooth muscle in vitro
72. 2)-induced bronchoconstriction in the anaesthetised guinea pig
73. 4-induced bronchoconstriction in guinea pigs
74. 2- and exercise-induced bronchoconstriction
75. 2- and histamine-induced bronchoconstriction in asthma, and relationship to plasma drug concentrations
76. 2-receptor antagonist on bradykinin-induced bronchoconstriction in asthma
77. 2 antagonist, reduces bronchial hyperresponsiveness in asthmatics
78. 2 synthetase inhibitor on antigen-induced bronchoconstriction in patients with asthma
79. 2 receptors
80. 2 receptors, to guinea pig lung membranes
81. Effect of YM158, a dual lipid mediator antagonist, on immediate and late asthmatic responses, and on airway hyperresponsiveness in guinea pigs
82. 2 receptors